CONMED Corp (CNMD) stock
Close on Nov 17, 2026Market cap $1.44BP/E 20.0Yield 1.24%
Earnings
Conmed's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Conmed's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Jan 27, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 28, 2026after the close | $335.60M | -0.7% | $0.66 | $1.04 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026during market hours | $343.50M | +0.4% | $0.77 | $1.38 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 29, 2026during market hours | $317.00M | -1.3% | $0.45 | $0.89 | Release |
| Q4 FY2025ended Dec 31, 2025 | Jan 28, 2026during market hours | $373.20M | +7.9% | $0.54 | $1.43 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025during market hours | $337.90M | +6.7% | $0.09 | $1.08 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 30, 2025during market hours | $342.30M | +3.1% | $0.69 | $1.15 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 30, 2025during market hours | $321.30M | +2.9% | $0.19 | $0.95 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 5, 2025during market hours | $345.90M | +5.8% | $1.08 | $1.34 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 30, 2024during market hours | $316.70M | +4.0% | $1.57 | $1.05 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024during market hours | $332.10M | +4.5% | $0.96 | $0.98 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 24, 2024during market hours | $312.30M | +5.7% | $0.63 | $0.79 | Release |
| Q4 FY2023ended Dec 31, 2023 | Jan 31, 2024during market hours | $327.00M | +30.3% | $1.05 | $1.06 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 25, 2023during market hours | $304.60M | +10.7% | $0.50 | $0.90 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 26, 2023during market hours | $317.70M | +14.6% | $0.43 | $0.83 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 26, 2023during market hours | $295.50M | +22.0% | $0.06 | $0.66 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 2, 2023during market hours | $250.90M | -8.4% | $0.86 | $0.42 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 26, 2022during market hours | $275.10M | +10.6% | $1.48 | $0.77 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 27, 2022during market hours | $277.20M | – | -$5.65 | $0.76 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022during market hours | $242.30M | – | $0.47 | $0.70 | Release |
| Q4 FY2021ended Dec 31, 2021 | Jan 26, 2022during market hours | $274.00M | – | $0.75 | $1.07 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 27, 2021during market hours | $248.80M | – | $0.47 | $0.80 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 28, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 28, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 27, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 28, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Conmed's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Net Sales (GAAP)GAAP | FY2026 | $1.36B – $1.37B | – | New | Oct 28, 2026 |
| Net Sales (GAAP)GAAP | FY2026 | $1.36B – $1.37B | $1.35B – $1.38B | Narrowed | Jul 29, 2026 |
| Net Sales Growth, as reportedGAAP | FY2026 | -1.2% – -0.1% | – | New | Jul 29, 2026 |
| Net Sales Growth, Constant Currencynon-GAAP | FY2026 | -1.7% – -0.7% | +5% – +6.5% | Lowered | Jul 29, 2026 |
| revenue from gastroenterology products | FY2026 | $14.50M – $17.50M | – | New | Apr 29, 2026 |
| Adjusted Diluted EPSnon-GAAP | FY2026 | $4.54 – $4.61 | – | New | Oct 28, 2026 |
| Adjusted Diluted EPSnon-GAAP | FY2026 | $4.48 – $4.60 | $4.30 – $4.45 | Raised | Jul 29, 2026 |
| Percentage Changenon-GAAP | FY2026 | -2.4% – +0.2% | – | New | Jul 29, 2026 |
Guidance vs results
The last range Conmed gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | adjusted diluted net earnings per share | $4.48 – $4.53 | $4.61Σ4Q | Above range |
| FY2025 | Revenue | $1.37B – $1.37B | $1.37BΣ4Q | Above range |
| Q3 FY2024 | Revenue | $315.00M – $318.00M | $316.70M | Within range |
Guidance history
Every forecast Conmed put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 28, 2026 | Adjusted Diluted EPS | FY2026 | $4.54 – $4.61 | New |
| Oct 28, 2026 | Net Sales (GAAP) | FY2026 | $1.36B – $1.37B | New |
| Jul 29, 2026 | Percentage Change | FY2026 | -2.4% – +0.2% | New |
| Jul 29, 2026 | Adjusted Diluted EPS | FY2026 | $4.48 – $4.60 | Raised |
| Jul 29, 2026 | Net Sales Growth, Constant Currency | FY2026 | -1.7% – -0.7% | Lowered |
| Jul 29, 2026 | Net Sales Growth, as reported | FY2026 | -1.2% – -0.1% | New |
| Jul 29, 2026 | Net Sales (GAAP) | FY2026 | $1.36B – $1.37B | Narrowed |
| Jul 29, 2026 | Net Sales Growth, Organic Constant Currency | FY2026 | +5% – +6% | Raised |
| Apr 29, 2026 | adjusted diluted net earnings per share | FY2026 | $4.30 – $4.45 | Reaffirmed |
| Apr 29, 2026 | revenue from gastroenterology products | FY2026 | $14.50M – $17.50M | New |
| Apr 29, 2026 | organic constant currency revenue growth | FY2026 | +5% – +6.5% | Raised |
| Apr 29, 2026 | reported revenue | FY2026 | $1.35B – $1.38B | Raised |
| Jan 28, 2026 | adjusted diluted net earnings per share | FY2026 | $4.30 – $4.45 | New |
| Jan 28, 2026 | reported revenue | FY2026 | $1.35B – $1.38B | New |
| Jan 28, 2026 | organic constant currency growth | FY2026 | +4.5% – +6% | New |
| Nov 5, 2025 | adjusted diluted net earnings per share | FY2025 | $4.48 – $4.53 | New |
| Nov 5, 2025 | reported revenue | FY2025 | $1.37B – $1.37B | New |
| Jul 30, 2025 | adjusted diluted net earnings per share | FY2025 | $4.40 – $4.55 | Lowered |
| Jul 30, 2025 | reported revenue | FY2025 | $1.36B – $1.38B | Raised |
| Apr 30, 2025 | full-year adjusted diluted net earnings per share | FY2025 | $4.45 – $4.60 | Raised |
| Apr 30, 2025 | full-year reported revenue | FY2025 | $1.35B – $1.38B | New |
| Feb 5, 2025 | adjusted diluted net earnings per share | FY2025 | $4.25 – $4.40 | New |
| Feb 5, 2025 | reported revenue | FY2025 | $1.34B – $1.37B | New |
| Feb 5, 2025 | constant currency growth | FY2025 | +4% – +6% | New |
| Oct 30, 2024 | adjusted diluted net earnings per share | FY2024 | $4.00 – $4.05 | Raised |
| Oct 30, 2024 | reported revenue | FY2024 | $1.30B – $1.31B | Lowered |
| Oct 4, 2024 | revenue | Q3 FY2024 | $315.00M – $318.00M | New |
| Jul 31, 2024 | adjusted diluted net earnings per share | FY2024 | $3.95 – $4.02 | Lowered |
| Jul 31, 2024 | reported revenue | FY2024 | $1.31B – $1.32B | Lowered |
| Apr 24, 2024 | adjusted diluted net earnings per share | FY2024 | $4.25 – $4.35 | Lowered |
| Apr 24, 2024 | reported revenue | FY2024 | $1.33B – $1.36B | Lowered |
| Jan 31, 2024 | adjusted diluted net earnings per share | FY2024 | $4.30 – $4.40 | New |
| Jan 31, 2024 | reported revenue | FY2024 | $1.34B – $1.37B | New |
| Oct 25, 2023 | adjusted diluted net earnings per share | FY2023 | $3.45 – $3.55 | Raised |
| Oct 25, 2023 | revenue | FY2023 | $1.24B – $1.26B | Raised |
| Jul 26, 2023 | adjusted diluted net earnings per share | FY2023 | $3.40 – $3.55 | Raised |
| Jul 26, 2023 | revenue | FY2023 | $1.23B – $1.26B | Raised |
| Apr 26, 2023 | adjusted diluted net earnings per share | FY2023 | $3.30 – $3.50 | Raised |
| Apr 26, 2023 | revenue | FY2023 | $1.21B – $1.25B | New |
| Feb 2, 2023 | Adjusted diluted net earnings per share | FY2023 | $3.20 – $3.45 | New |
| Feb 2, 2023 | reported revenue | FY2023 | $1.17B – $1.22B | New |
| Oct 26, 2022 | adjusted diluted net earnings per share | FY2022 | $3.21 – $3.28 | Lowered |
| Oct 26, 2022 | revenue | FY2022 | $1.10B – $1.12B | Narrowed |
| Jul 27, 2022 | adjusted diluted net earnings per share | FY2022 | $3.40 – $3.55 | Lowered |
| Jul 27, 2022 | revenue | FY2022 | $1.10B – $1.14B | Lowered |
| May 4, 2022 | adjusted diluted net earnings per share | FY2022 | $3.50 – $3.65 | Lowered |
| May 4, 2022 | revenue | FY2022 | $1.11B – $1.15B | Raised |
| Jan 26, 2022 | adjusted diluted net earnings per share | FY2022 | $3.60 – $3.85 | New |
| Jan 26, 2022 | revenue | FY2022 | $1.08B – $1.13B | New |
| Oct 27, 2021 | adjusted diluted net earnings per share | FY2021 | $3.18 – $3.23 | New |
| Oct 27, 2021 | revenue | FY2021 | $1.02B – $1.04B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Conmed filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- Results
- News
- Results
- Update
- Results
See a number that looks wrong?